Mobility key to quality of life for MS sufferers

(Medical Xpress) -- Reduced mobility among patients with secondary‐progressive multiple sclerosis (SPMS) is associated with a decline in quality of life, according to new data presented today at the 7th World Congress of NeuroRehabilitation in Melbourne.

According to  UNSW's Associate Professor of Neuroscience, Arun Krishnan, whether or not symptomatic treatments that improve might also make a positive contribution to ’ quality of life is an important focus for future research.

Professor Krishnan’s research looked at data derived from 160 placebo treated MS patients whose speed was measured using the Timed 25 Foot Walk (T25FW) test and then correlated this with quality of life measures (including a physical component summary scale, physical function, bodily pain and general health) over a two year period.

Overall, slower walking speed was associated with a decline in quality of life over two years. This association between walking speed and quality of life was independent of any treatment because the subjects were derived from the placebo arm of a clinical trial.

At two years, data showed that patients walked on average 19% slower. Physical component scores (like physical function and general health) declined in patients who walked more than 0.15 metres/second slower at month 24 compared with baseline and improved in the small number who walked greater than 0.15 metres/second faster.

Professor Krishnan says the findings are important as they suggest a clinical focus on the treatment of reduced mobility in MS patients might deliver significant benefits in the future to patients with secondary‐progressive .

“There are limited treatment options for patients whose MS is progressing and who are at the ‘secondary progressive’ phase. Whether treatments that improve walking also positively influence health‐related quality of life in MS patients is certainly an intriguing question for the future,” said Professor Krishnan.

add to favorites email to friend print save as pdf

Related Stories

Smoking marijuana impairs cognitive function in MS patients

Feb 13, 2008

People with multiple sclerosis (MS) who smoke marijuana are more likely to have emotional and memory problems, according to research published February 13, 2008, in the online edition of Neurology, the medical journal of the ...

Drug improves mobility for some MS patients

Feb 27, 2009

The experimental drug fampridine (4-aminopyridine) improves walking ability in some individuals with multiple sclerosis (MS). That is the conclusion of a multi-center Phase 3 clinical trial, the results of which were published ...

Muscling in on multiple sclerosis

Jan 26, 2012

Multiple sclerosis (MS), a neurodegenerative disease, causes periodic attacks of neurologic symptoms such as limb weakness and mobility defects. And while MS patients' walking abilities and muscle strength are examined on ...

Recommended for you

Recorded Ebola deaths top 7,000

1 hour ago

The worst Ebola outbreak on record has now killed more than 7,000 people, with many of the latest deaths reported in Sierra Leone, the World Health Organization said as United Nations Secretary-General Ban ...

Liberia holds Senate vote amid Ebola fears (Update)

5 hours ago

Health workers manned polling stations across Liberia on Saturday as voters cast their ballots in a twice-delayed Senate election that has been criticized for its potential to spread the deadly Ebola disease.

Evidence-based recs issued for systemic care in psoriasis

Dec 19, 2014

(HealthDay)—For appropriately selected patients with psoriasis, combining biologics with other systemic treatments, including phototherapy, oral medications, or other biologic, may result in greater efficacy ...

Bacteria in caramel apples kills at least four in US

Dec 19, 2014

A listeria outbreak believed to originate from commercially packaged caramel apples has killed at least four people in the United States and sickened 28 people since November, officials said Friday.

Steroid-based treatment may answer needs of pediatric EoE patients

Dec 19, 2014

A new formulation of oral budesonide suspension, a steroid-based treatment, is safe and effective in treating pediatric patients with eosinophilic esophagitis (EoE), according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.